Results 181 to 190 of about 3,180,492 (237)
Antibody-directed urokinase: a specific fibrinolytic agent. [PDF]
Science, 1985 A specific fibrinolytic agent was synthesized by covalently coupling urokinase to a monoclonal antibody that was fibrin-specific and did not cross-react with fibrinogen.
C. Bode, G. Matsueda, K. Hui, E. Haber
semanticscholar +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Tenecteplase: a promising new fibrinolytic agent.
Dimensions of Critical Care Nursing, 2001Acute coronary syndrome can mean anything from unstable angina to acute myocardial infarction (MI) with ST-segment elevation. Tenecteplase, a new fibrinolytic agent used to treat ST-segment elevation acute MI, has some advantages over other fibrinolytic ...
Marla J. De Jong +1 more
semanticscholar +4 more sources
Treatment of thrombophlebitis with a fibrinolytic agent, with special references to side effects.
The American Journal of Cardiology, 1960Abstract 1. 1. Fibrinolysin was administered to seventy-one patients in 218 separate intravenous infusions. Each infusion contained 50,000 to 100,000 Merck units dissolved in 100 to 250 ml. of 5 per cent glucose in water and was given over a half- to two-hour period. Side effects were limited to hyperpyrexia of 2 °F.
N. D. Davis, B. Carroll, S. H. Schwartz
semanticscholar +4 more sources
Progress in Cardiovascular Diseases, 1979
W ITHOUT question, degenerative vascular disease remains the major cause of death and morbidity in the Western world. In the United Kingdom, cardiovascular disease is responsible for about 50% of all deaths in men aged 45-54 yr, and this must be compared with only 25% of deaths in this age group resulting from cancers.’ Although little direct proof ...
J. F. Davidson, Isobel D. Walker
openaire +3 more sources
W ITHOUT question, degenerative vascular disease remains the major cause of death and morbidity in the Western world. In the United Kingdom, cardiovascular disease is responsible for about 50% of all deaths in men aged 45-54 yr, and this must be compared with only 25% of deaths in this age group resulting from cancers.’ Although little direct proof ...
J. F. Davidson, Isobel D. Walker
openaire +3 more sources
Development of New Fibrinolytic Agents
Current Pharmaceutical Design, 2006Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic, which removes the thrombus from the circulation.
Shigeru Ueshima, Osamu Matsuo
openaire +2 more sources
The clinical use of fibrinolytic agents
The American Journal of Surgery, 1977Two fibrinolytic drugs, streptokinase and urokinase, have undergone extensive clinical evaluation in the past fifteen years. Current evidence suggests that these agents may become the drugs of choice in the treatment of certain patients with venous thrombosis and pulmonary embolism.
John M. Porter, Scott H. Goodnight
openaire +3 more sources
2006
The fibrinolytic system plays a vital role in maintaining vital organ homeostasis. Fibrinolysis, defined as the dissolution of fibrin (the major scaffold for intravascular thrombus), is the process that regulates thrombus growth after hemostasis has been achieved, thus preserving tissue perfusion.
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
The fibrinolytic system plays a vital role in maintaining vital organ homeostasis. Fibrinolysis, defined as the dissolution of fibrin (the major scaffold for intravascular thrombus), is the process that regulates thrombus growth after hemostasis has been achieved, thus preserving tissue perfusion.
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
Fibrinolytic agents for peripheral arterial occlusion
Cochrane Database of Systematic Reviews, 2010Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA) have increasingly become established as first line agents for peripheral arterial thrombolysis.
Iain Robertson +2 more
openaire +4 more sources